A detailed history of Vident Advisory, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Vident Advisory, LLC holds 10,848 shares of MYGN stock, worth $287,146. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,848
Previous 12,451 12.87%
Holding current value
$287,146
Previous $265 Million 0.04%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$17.98 - $25.47 $28,821 - $40,828
-1,603 Reduced 12.87%
10,848 $265 Million
Q1 2024

May 14, 2024

SELL
$17.59 - $23.59 $6,174 - $8,280
-351 Reduced 2.74%
12,451 $265 Million
Q4 2023

Feb 14, 2024

BUY
$13.91 - $21.32 $10,029 - $15,371
721 Added 5.97%
12,802 $245 Million
Q3 2023

Feb 21, 2024

SELL
$15.99 - $23.22 $11,528 - $16,741
-721 Reduced 5.63%
12,081 $194 Million
Q3 2023

Nov 14, 2023

BUY
$15.99 - $23.22 $193,175 - $280,520
12,081 New
12,081 $194 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $2.13B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.